The online version of this article (doi:10.1186/1471-230X-14-96) contains supplementary material, which is available to authorized users.
Conglong Xue, Zhenwei Zhang, Honglan Yu contributed equally to this work.
The authors have no competing interests to declare.
HPS, MY and CLX have conceived and designed the experiments, as well as have been involved in drafting the manuscript. CLX and ZWZ have performed the experiments. HLY and MY have participated inclinical data and information collection. CLX, KTY and TY have analyzed the date. All authors read and approved the final manuscript.
Cytosolic nonspecific dipetidase (CN2) belongs to the family of M20 metallopeptidases. It was stated in previous articles that higher expression levels of CN2 were observed in renal cell carcinoma and breast cancer. Our study explored the correlation between CN2 and colon carcinogenesis.
We analysed the relationship between 183 patients clinicopathological characteristics and its CN2 expression. To detect the levels of CN2 in colon cancer cell lines and colon cancer tissues by western blot. To verify cell proliferation in colon cancer cells with knockdown of CNDP2 and explore the causes of these phenomena.
The expression levels of CN2 in clinical colon tumors and colon cancer cell lines were significantly higher than that in normal colon mucosa and colon cell lines. The difference in CN2 levels was associated with tumor location (right- and left-sided colon cancer), but there was no significant association with age, gender, tumor size, tumor grade, tumor stage or serum carcinoembryonic antigen (CEA). Knockdown of CNDP2 inhibited cell proliferation, blocked cell cycle progression and retarded carcinogenesis in an animal model. The signaling pathway through which knockdown of CNDP2 inhibited cell proliferation and tumorigenesis involved in EGFR, cyclin B1 and cyclin E.
Knockdown of CNDP2 can inhibit the proliferation of colon cancer in vitro and retarded carcinogenesis in vivo.
Hutchins G, Southward K, Handley K, Magill L, Beaumont C, Stahlschmidt J, Richman S, Chambers P, Seymour M, Kerr D, Gray R, Quirke P: Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. J Clin Oncol. 2011, 29: 1261-1270. 10.1200/JCO.2010.30.1366. CrossRefPubMed
Teufel M, Saudek V, Ledig JP, Bernhardt A, Boularand S, Carreau A, Cairns NJ, Carter C, Cowley DJ, Duverger D, Ganzhorn AJ, Guenet C, Heintzelmann B, Laucher V, Sauvage C, Smirnova T: Sequence identification and characterization of human carnosinase and a closely related non-specific dipeptidase. J Biol Chem. 2003, 278: 6521-6531. 10.1074/jbc.M209764200. CrossRefPubMed
Ichinose Y, Genka K, Koike T, Kato H, Watanabe Y, Mori T, Iioka S, Sakuma A, Ohta M: NK421 Lung Cancer Surgery Group. Randomized double-blind placebo-controlled trial of bestatin in patients with resected stage I squamous-cell lung carcinoma. J Natl Cancer Inst. 2003, 95: 605-610. 10.1093/jnci/95.8.605. CrossRefPubMed
Okamura N, Masuda T, Gotoh A, Shirakawa T, Terao S, Kaneko N, Suganuma K, Watanabe M, Matsubara T, Seto R, Matsumoto J, Kawakami M, Yamamori M, Nakamura T, Yagami T, Sakaeda T, Fujisawa M, Nishimura O, Okumura K: Quantitative proteomic analysis to discover potential diagnostic markers and therapeutic targets in human renal cell carcinoma. Proteomics. 2008, 8: 3194-3203. 10.1002/pmic.200700619. CrossRefPubMed
Lee JH, Giovannetti E, Hwang JH, Petrini I, Wang Q, Voortman J, Wang Y, Steinberg SM, Funel N, Meltzer PS, Wang Y, Giaccone G: Loss of 18q22.3 involving the carboxypeptidase of glutamate-like gene is associated with poor prognosis in resected pancreatic cancer. Clin Cancer Res. 2012, 18: 524-533. 10.1158/1078-0432.CCR-11-1903. CrossRefPubMed
Benedix F, Kube R, Meyer F, Schmidt U, Gastinger I, Lippert H: Colon/Rectum Carcinomas (Primary Tumor) Study Group. Comparison of 17,641 patients with right- and left-sided colon cancer: differences in epidemiology, perioperative course, histology, and survival. Dis Colon Rectum. 2010, 53: 57-64. 10.1007/DCR.0b013e3181c703a4. CrossRefPubMed
Pinto AE, Silva GL, Pereira T, Cabrera RA, Santos JR, Leite V: S-phase fraction and ploidy as predictive markers in primary disease and recurrence of papillary thyroid carcinoma. Clin Endocrinol (Oxf). 2012, 77: 302-309. 10.1111/j.1365-2265.2012.04363.x. CrossRef
Bazan V, Migliavacca M, Zanna I, Tubiolo C, Corsale S, Calò V, Amato A, Cammareri P, Latteri F, Grassi N, Fulfaro F, Porcasi R, Morello V, Nuara RB, Dardanoni G, Salerno S, Valerio MR, Dusonchet L, Gerbino A, Gebbia N, Tomasino RM, Russo A: DNA ploidy and S-phase fraction, but not p53 or NM23-H1 expression, predict outcome in colorectal cancer patients. Result of a 5-year prospective study. J Cancer Res Clin Oncol. 2002, 128: 650-658. 10.1007/s00432-002-0394-6. CrossRefPubMed
Archer SY, Johnson J, Kim HJ, Ma Q, Mou H, Daesety V, Meng S, Hodin RA: The histone deacetylase inhibitor butyrate downregulates cyclin B1 gene expression via a p21/WAF-1-dependent mechanism in human colon cancer cells. Am J Physiol Gastrointest Liver Physiol. 2005, 289: 696-703.
- Up-regulation of CNDP2 facilitates the proliferation of colon cancer
- BioMed Central
Neu im Fachgebiet Innere Medizin
Meistgelesene Bücher aus der Inneren Medizin
Mail Icon II